Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 31 -40 of 285 Show results per page	View Search Criteria \| Help With Results


31.		Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				EMR 62202-013 NCT00154102

Last Modified: 9/12/2008 First Published: 12/9/2005


32.		Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				18 and over				NCI				CALGB-C80405 C80405, SWOG-C80405, NCT00265850


33.		IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				18 to 75				Other				HGCSG0601 IFOX study, NCT00316745

Last Modified: 6/16/2008 First Published: 7/14/2006


34.		Phase III Study of High-Dose Combination Chemotherapy Comprising Vincristine, Irinotecan Hydrochloride, Ifosfamide, Etoposide, Doxorubicin Hydrochloride, Cyclophosphamide, and Dactinomycin and Radiotherapy in Patients With Newly Diagnosed, High-Risk, Metastatic Rhabdomyosarcoma or Ectomesenchymoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Under 50				NCI				COG-ARST0431 ARST0431, NCT00354744

Last Modified: 6/16/2008 First Published: 7/6/2007


35.		Phase III Randomized Study of Irinotecan Hydrochloride-Based Chemotherapy and Cetuximab With Versus Without Bevacizumab in Patients With Metastatic Colorectal Cancer That Progressed on First-Line Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				18 and over				NCI				SWOG-S0600 S0600, CALGB-SWOG-S0600, ECOG-SWOG-S0600, CAN-NCIC-SWOG-S0600, NCCTG-SWOG-S0600, NCT00499369


36.		A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				BO20696 NCT00642577

Last Modified: 8/1/2000 First Published: 4/1/1998


37.		Phase I/II Study of Amifostine as a Protective Agent for Irinotecan Toxicities in Patients with Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-HSPC-970304601B ALZA-UCLA-HSPC-970304601B, NCI-G98-1390, NCT00003225

Last Modified: 9/16/2005 First Published: 6/1/1998


38.		Phase I/II Study of Irinotecan in Patients with Recurrent Malignant Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NABTT-9711 JHOC-NABTT-9711, NCT00003301, NABTT-9711

Last Modified: 4/1/2000 First Published: 8/1/1998


39.		Phase I/II Study of Irinotecan and Radiotherapy in Patients with Unresectable or Locally Recurrent Large Bowel Cancer (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				MUSC-7532 HCC/MUSC-GI-01, NCI-V98-1420, NCT00003344

Last Modified: 12/1/2002 First Published: 9/1/1998


40.		Phase I/II Study of Iodine I 131 Antitenascin Monoclonal Antibody 81C6 via Surgically Created Cystic Resection Cavity after Radiotherapy in Patients With Primary Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				DUMC-1533-02-8R5ER DUMC-1533-01-8R4, DUMC-1373-97-9, DUMC-1408-98-9R1, DUMC-1533-00-8R3, DUMC-1570-99-9R2, DUMC-97107, NCI-5P0NS20023, NCI-G98-1472, NCT00003484

Select All on One Page


					< Previous 1 2 3 4 5 6 7 Next >

| | | | | | | |

A Service of the National Cancer Institute